Molecular Partners latest IPO failure, but others get through

By Andrew Griffin, Olivier Holmey
23 Oct 2014

Swiss biotech firm Molecular Partners became the latest victim of the recent bout of volatility in Europe’s markets, as it put its planned listing on hold on Tuesday. More deals could yet fail, bankers said.

The book had not attracted enough investor demand to support an IPO, said a banker on the deal.

“We were very, very close to getting a book covered," said the banker. "But at the end of the day it’s been a pretty rough couple of weeks in the IPO market, ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial

Want to learn more? View subscription options